FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II)

Who is this study for? Adult female patients with Stage IB to IVA Cervical Squamous Cell Carcinoma, Adenocarcinoma, or Adenosquamous Carcinoma
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Nearly all cervical cancers are caused by the human papilloma virus (HPV), which can be detected in cancer tissue by laboratory tests. There is evidence that the virus can also be detected from a blood sample to monitor the effects of treatment. Previous studies have shown that a special test called 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET-CT) at 3 months after treatment may predict survival in cervical cancer. The purpose of this study is to see how well the FDG-PET Scan and blood tests for HPV can detect leftover cervical cancer cells after treatment. This study is not a particular form of treatment and patients will receive standard of care treatment.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

• Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IB-IVA

• 3.1.2 Planned for radical radiotherapy and concurrent cisplatin chemotherapy.

• 3.1.3 Age ≥ 18 years.

Locations
Other Locations
Canada
University Health Network, The Princess Margaret
RECRUITING
Toronto
Contact Information
Primary
Kathy Han, MD
kathy.han@rmp.uhn.ca
416 946 4501
Time Frame
Start Date: 2019-04-23
Estimated Completion Date: 2026-12-30
Participants
Target number of participants: 64
Treatments
Experimental: FDG PET Scan
\[F-18\] - FDG PET Scan and blood sample to measure HPV DNA
Sponsors
Leads: University Health Network, Toronto
Collaborators: Sunnybrook Health Sciences Centre

This content was sourced from clinicaltrials.gov